Last reviewed · How we verify
NXP900
At a glance
| Generic name | NXP900 |
|---|---|
| Sponsor | Nuvectis Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers (PHASE1)
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NXP900 CI brief — competitive landscape report
- NXP900 updates RSS · CI watch RSS
- Nuvectis Pharma, Inc. portfolio CI